Trial Profile
Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2013
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 03 Dec 2013 New trial record